(Indian Business Insight Via Acquire Media NewsEdge) The $3.2 billion acquisition of Ranbaxy Laboratories Ltd (RLL) by Sun Pharmaceutical Industries will be a test for the industry friendliness of the Competition Commission of India (CCI). The CCI has so far cleared most merger and acquisition (M&A) applications that have come before it. The Sun-Ranbaxy transaction is the first merger deal that has received a show- cause notice from CCI, since the Government of India amended the merger control provision in 2011. The acquisition of RLL by Sun has given Sun a dominant position in the Indian drug market. The CCI may ask Sun's competitors if they have any objection to the deal.